United Therapeutics (UTHR) opened 2026 with Q1 revenue of US$781.5 million and basic EPS of US$6.32, alongside trailing twelve month revenue of US$3.2 billion and EPS of US$29.29. These figures place the latest quarter within a broader earnings run. Over recent periods, revenue has moved from US$735.9 million in Q4 2024 to the current US$781.5 million. Basic EPS has ranged between US$6.32 and US$8.41 across the last five quarters, giving investors a clearer view of profit per share as margins remain stable.

See our full analysis for United Therapeutics.

With the headline numbers on the table, the next step is to see how this earnings profile compares with the most widely discussed narratives around United Therapeutics and to consider where those stories might need updating.

40.6% net margin keeps profitability high

• Over the last 12 months United Therapeutics converted US$3.2b of revenue into US$1.3b of net income, which works out to a 40.6% net margin, slightly above the prior year’s 40.4%.
• Consensus narrative points to strong recurring profitability as a support for long term growth, and this margin level sits in that camp. Trailing earnings growth of 6.3% over the last year versus 21.9% per year over five years shows profit is expanding from a high base more slowly than before, which is more cautious than some long term growth stories imply.
  • Net income over the last year at US$1.3b against US$3.2b of revenue fits the view of a high quality earnings profile, even as the pace of growth cools relative to the multi year trend.
  • Analysts expecting earnings growth of 16.4% per year and revenue growth of 14.6% per year are effectively sitting between that slower recent growth and the faster five year history, which is why many investors treat this as a steady compounder rather than a hyper growth story.

Valuation sits between peers and DCF fair value

• At a P/E of 20.3x, the stock trades above the wider US Biotechs industry average of 17.6x but below a 31.1x peer average, while the provided DCF fair value of US$1,741.59 is far above the current US$596.76 share price.
• Bulls argue that long term growth and pipeline optionality justify a richer valuation, and the large gap between the current price and the DCF fair value strongly supports that view. The higher P/E than the broader industry and analysts’ price target of US$643.69 create a more grounded reference point than the DCF alone.
  • Forecast earnings growth of 16.4% per year and revenue growth of 14.6% per year, both modestly above the referenced US market, help explain why the stock trades above the broader biotech P/E but not at the higher peer multiple.
  • The DCF fair value that is very far above the market price reinforces the optimistic narrative on cash generation and margin durability, although the more modest gap between today’s price and the US$643.69 analyst target shows that not all valuation frameworks point to the same upside.

Have a closer look at how bullish investors connect this earnings profile to long term growth potential through the 🐂 United Therapeutics Bull Case.

Slower 6.3% earnings growth tests bearish worries

• Trailing 12 month earnings growth of 6.3% is well below the 21.9% per year earned over the last five years, even as the company maintained a 40.6% net margin and generated US$1.3b of net income.
• Bears highlight dependence on a few therapies and rising competition as reasons growth could cool, and the step down from the five year earnings pace lines up with that concern. The combination of above market forecast growth and a P/E below the 31.1x peer average means the stock is not priced like a company whose growth has stalled completely.
  • Revenue of US$3.2b over the last year alongside a still high margin suggests the core business remains solid, which sits somewhat at odds with the most cautious scenarios that assume sharp profit erosion.
  • Analysts expecting revenue and earnings growth in the mid teens, rather than low single digits, indicate that many market observers see current growth moderation as a slower phase rather than a collapse, leaving room for different views on how competition and pricing will play out.

Skeptical about how much growth is left in the story? See how more cautious investors frame the same numbers in the 🐻 United Therapeutics Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for United Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seen both the bullish and cautious angles yet still unsure where you land? It is worth checking the details yourself and deciding how durable these rewards really look using the 3 key rewards.

See What Else Is Out There

United Therapeutics combines high margins with a 6.3% earnings growth rate that trails its 21.9% five year pace, which leaves some investors questioning the stock’s current P/E and upside.

If that slower growth has you hesitating, it makes sense to compare this profile with companies that still look attractively priced by checking out the 44 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.